Media coverage about Champions Oncology (NASDAQ:CSBR) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Champions Oncology earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.1150208818105 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
NASDAQ CSBR traded up $0.30 on Wednesday, hitting $6.92. 2,503 shares of the stock traded hands, compared to its average volume of 35,331. The firm has a market cap of $69.31 million, a price-to-earnings ratio of -10.34 and a beta of -0.92. Champions Oncology has a 12 month low of $2.19 and a 12 month high of $7.10.
A number of research analysts recently weighed in on CSBR shares. Dawson James initiated coverage on Champions Oncology in a research note on Tuesday, May 15th. They set a “buy” rating and a $10.00 price target on the stock. ValuEngine raised Champions Oncology from a “hold” rating to a “buy” rating in a report on Tuesday, June 5th.
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.